Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Investors overview.gif
Investor Relations Contact:
ir@anacor.com
Phone: 650-543-7575

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its novel boron chemistry platform. We currently have five product candidates in clinical development. Our three lead product candidates include two topically administered dermatologic compounds— tavaborole (formerly AN2690) , an antifungal for the treatment of onychomycosis, and AN2728, an anti-inflammatory for the treatment of psoriasis, as well as a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria—GSK2251052, or GSK '052 (formerly referred to as AN3365). In addition, we are developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. We have entered into and are seeking partnerships to expand the therapeutic application and commercial value of our boron chemistry platform.

View all »Recent Releases

Mar 31, 2014
Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-to-Moderate Atopic Dermatitis

Mar 19, 2014
Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer

View all »Events & Presentations

Mar 13, 2014 at 2:00 PM PT
Anacor Fourth Quarter 2013 Financial Results Conference Call

Mar 3, 2014 at 3:30 PM ET
Cowen & Company 34th Annual Health Care Conference

Receive Email Alerts

Sign up to receive e-mail alerts whenever Anacor posts new information to the site.



(ANAC): NASDAQ
Price: 17.62 Change: +1.52
High: 18.40 %Change: 9.407%
Low: 16.35 Volume: 583,300